DD229151A5 - Verfahren zur herstellung von gewebeplasminogenaktivatoren - Google Patents

Verfahren zur herstellung von gewebeplasminogenaktivatoren Download PDF

Info

Publication number: DD229151A5
Authority: DD; German Democratic Republic
Prior art keywords: gpa; yeast; dna; pho5; promoter
Prior art date: 1983-11-21

Application number

DD84269628A

Other languages

German (de)

English (en)

Inventor

Bernd Meyhack

Albert Hinnen

Original Assignee

Ciba Geigy Ag

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1983-11-21

Filing date

1984-11-19

Publication date

1985-10-30

1983-11-21 Priority claimed from GB838331045A external-priority patent/GB8331045D0/en

1984-11-19 Application filed by Ciba Geigy Ag filed Critical Ciba Geigy Ag

1985-10-30 Publication of DD229151A5 publication Critical patent/DD229151A5/de

Links

238000004519 manufacturing process Methods 0.000 title claims abstract description 26
240000004808 Saccharomyces cerevisiae Species 0.000 claims abstract description 215
108090000623 proteins and genes Proteins 0.000 claims abstract description 119
239000013598 vector Substances 0.000 claims abstract description 97
238000000034 method Methods 0.000 claims abstract description 86
239000000203 mixture Substances 0.000 claims abstract description 55
102000004169 proteins and genes Human genes 0.000 claims abstract description 46
102000003978 Tissue Plasminogen Activator Human genes 0.000 claims abstract description 18
108090000373 Tissue Plasminogen Activator Proteins 0.000 claims abstract description 18
229960000187 tissue plasminogen activator Drugs 0.000 claims abstract description 18
238000002360 preparation method Methods 0.000 claims abstract description 17
230000008569 process Effects 0.000 claims abstract description 10
235000015097 nutrients Nutrition 0.000 claims abstract description 4
235000014680 Saccharomyces cerevisiae Nutrition 0.000 claims description 200
101150012394 PHO5 gene Proteins 0.000 claims description 188
210000004027 cell Anatomy 0.000 claims description 97
108091026890 Coding region Proteins 0.000 claims description 69
108010076504 Protein Sorting Signals Proteins 0.000 claims description 42
238000006243 chemical reaction Methods 0.000 claims description 27
108091028043 Nucleic acid sequence Proteins 0.000 claims description 26
230000005030 transcription termination Effects 0.000 claims description 19
229920002684 Sepharose Polymers 0.000 claims description 18
238000000746 purification Methods 0.000 claims description 15
210000000349 chromosome Anatomy 0.000 claims description 14
230000002759 chromosomal effect Effects 0.000 claims description 13
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 12
108700026244 Open Reading Frames Proteins 0.000 claims description 9
238000001042 affinity chromatography Methods 0.000 claims description 9
238000004587 chromatography analysis Methods 0.000 claims description 9
239000012531 culture fluid Substances 0.000 claims description 7
239000003112 inhibitor Substances 0.000 claims description 7
201000001441 melanoma Diseases 0.000 claims description 7
150000003839 salts Chemical class 0.000 claims description 7
239000007788 liquid Substances 0.000 claims description 6
229910052757 nitrogen Inorganic materials 0.000 claims description 6
238000012545 processing Methods 0.000 claims description 6
238000013519 translation Methods 0.000 claims description 5
OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 4
108010062580 Concanavalin A Proteins 0.000 claims description 4
229910052799 carbon Inorganic materials 0.000 claims description 4
230000013595 glycosylation Effects 0.000 claims description 4
238000006206 glycosylation reaction Methods 0.000 claims description 4
102000005593 Endopeptidases Human genes 0.000 claims description 3
108010059378 Endopeptidases Proteins 0.000 claims description 3
125000003147 glycosyl group Chemical group 0.000 claims description 3
108091005608 glycosylated proteins Proteins 0.000 claims description 3
102000035122 glycosylated proteins Human genes 0.000 claims description 3
210000003292 kidney cell Anatomy 0.000 claims description 3
239000000137 peptide hydrolase inhibitor Substances 0.000 claims description 3
206010005003 Bladder cancer Diseases 0.000 claims description 2
201000009030 Carcinoma Diseases 0.000 claims description 2
229940124158 Protease/peptidase inhibitor Drugs 0.000 claims description 2
208000006265 Renal cell carcinoma Diseases 0.000 claims description 2
201000001531 bladder carcinoma Diseases 0.000 claims description 2
210000000481 breast Anatomy 0.000 claims description 2
210000002950 fibroblast Anatomy 0.000 claims description 2
206010024627 liposarcoma Diseases 0.000 claims description 2
238000001179 sorption measurement Methods 0.000 claims description 2
208000010570 urinary bladder carcinoma Diseases 0.000 claims description 2
239000013612 plasmid Substances 0.000 abstract description 163
210000005253 yeast cell Anatomy 0.000 abstract description 34
241000235070 Saccharomyces Species 0.000 abstract description 3
239000003814 drug Substances 0.000 abstract description 2
108020004414 DNA Proteins 0.000 description 267
239000012634 fragment Substances 0.000 description 203
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 143
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 102
ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 64
238000010276 construction Methods 0.000 description 52
230000029087 digestion Effects 0.000 description 52
239000002609 medium Substances 0.000 description 52
239000011780 sodium chloride Substances 0.000 description 51
HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 48
239000007983 Tris buffer Substances 0.000 description 46
LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 46
108091008146 restriction endonucleases Proteins 0.000 description 44
230000000694 effects Effects 0.000 description 41
235000018102 proteins Nutrition 0.000 description 41
239000000243 solution Substances 0.000 description 40
239000000499 gel Substances 0.000 description 39
QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 38
KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 38
239000011543 agarose gel Substances 0.000 description 32
239000002773 nucleotide Substances 0.000 description 31
125000003729 nucleotide group Chemical group 0.000 description 31
102000012410 DNA Ligases Human genes 0.000 description 30
108010061982 DNA Ligases Proteins 0.000 description 30
108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 30
241000588724 Escherichia coli Species 0.000 description 29
108010051457 Acid Phosphatase Proteins 0.000 description 26
102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 26
229940046166 oligodeoxynucleotide Drugs 0.000 description 24
239000000047 product Substances 0.000 description 24
102000013563 Acid Phosphatase Human genes 0.000 description 23
229960000723 ampicillin Drugs 0.000 description 22
AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 22
238000002844 melting Methods 0.000 description 22
GZCWLCBFPRFLKL-UHFFFAOYSA-N 1-prop-2-ynoxypropan-2-ol Chemical compound CC(O)COCC#C GZCWLCBFPRFLKL-UHFFFAOYSA-N 0.000 description 21
BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 20
230000009466 transformation Effects 0.000 description 20
229920001817 Agar Polymers 0.000 description 19
239000008272 agar Substances 0.000 description 19
238000000605 extraction Methods 0.000 description 19
238000011534 incubation Methods 0.000 description 19
150000001413 amino acids Chemical group 0.000 description 18
229950003499 fibrin Drugs 0.000 description 18
230000008018 melting Effects 0.000 description 18
OSBLTNPMIGYQGY-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;2-[2-[bis(carboxymethyl)amino]ethyl-(carboxymethyl)amino]acetic acid;boric acid Chemical compound OB(O)O.OCC(N)(CO)CO.OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O OSBLTNPMIGYQGY-UHFFFAOYSA-N 0.000 description 17
241001131785 Escherichia coli HB101 Species 0.000 description 17
102000009123 Fibrin Human genes 0.000 description 17
108010073385 Fibrin Proteins 0.000 description 17
108010014303 DNA-directed DNA polymerase Proteins 0.000 description 16
102000016928 DNA-directed DNA polymerase Human genes 0.000 description 16
KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 16
239000000872 buffer Substances 0.000 description 16
239000002299 complementary DNA Substances 0.000 description 16
238000002955 isolation Methods 0.000 description 16
102000004190 Enzymes Human genes 0.000 description 15
108090000790 Enzymes Proteins 0.000 description 15
108700039691 Genetic Promoter Regions Proteins 0.000 description 15
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 15
230000001580 bacterial effect Effects 0.000 description 15
229940088598 enzyme Drugs 0.000 description 15
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 13
DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 13
230000014509 gene expression Effects 0.000 description 13
238000010348 incorporation Methods 0.000 description 13
239000008103 glucose Substances 0.000 description 12
239000003550 marker Substances 0.000 description 12
239000002953 phosphate buffered saline Substances 0.000 description 12
102000001938 Plasminogen Activators Human genes 0.000 description 11
229940024606 amino acid Drugs 0.000 description 11
239000011575 calcium Substances 0.000 description 11
238000005119 centrifugation Methods 0.000 description 11
229940127126 plasminogen activator Drugs 0.000 description 11
230000010076 replication Effects 0.000 description 11
229920000936 Agarose Polymers 0.000 description 10
210000002421 cell wall Anatomy 0.000 description 10
238000003776 cleavage reaction Methods 0.000 description 10
238000010367 cloning Methods 0.000 description 10
108020004999 messenger RNA Proteins 0.000 description 10
230000007017 scission Effects 0.000 description 10
210000001519 tissue Anatomy 0.000 description 10
OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 9
ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 9
108010001014 Plasminogen Activators Proteins 0.000 description 9
239000004098 Tetracycline Substances 0.000 description 9
229920004890 Triton X-100 Polymers 0.000 description 9
239000013504 Triton X-100 Substances 0.000 description 9
229910052791 calcium Inorganic materials 0.000 description 9
239000013613 expression plasmid Substances 0.000 description 9
238000000855 fermentation Methods 0.000 description 9
230000004151 fermentation Effects 0.000 description 9
239000011159 matrix material Substances 0.000 description 9
238000001556 precipitation Methods 0.000 description 9
230000008929 regeneration Effects 0.000 description 9
238000011069 regeneration method Methods 0.000 description 9
229960002180 tetracycline Drugs 0.000 description 9
229930101283 tetracycline Natural products 0.000 description 9
235000019364 tetracycline Nutrition 0.000 description 9
150000003522 tetracyclines Chemical class 0.000 description 9
239000011573 trace mineral Substances 0.000 description 9
235000013619 trace mineral Nutrition 0.000 description 9
238000001712 DNA sequencing Methods 0.000 description 8
108091036060 Linker DNA Proteins 0.000 description 8
238000004458 analytical method Methods 0.000 description 8
AIYUHDOJVYHVIT-UHFFFAOYSA-M caesium chloride Chemical compound [Cl-].[Cs+] AIYUHDOJVYHVIT-UHFFFAOYSA-M 0.000 description 8
RGWHQCVHVJXOKC-SHYZEUOFSA-J dCTP(4-) Chemical compound O=C1N=C(N)C=CN1[C@@H]1O[C@H](COP([O-])(=O)OP([O-])(=O)OP([O-])([O-])=O)[C@@H](O)C1 RGWHQCVHVJXOKC-SHYZEUOFSA-J 0.000 description 8
230000002255 enzymatic effect Effects 0.000 description 8
230000003480 fibrinolytic effect Effects 0.000 description 8
230000012010 growth Effects 0.000 description 8
ZNNZYHKDIALBAK-UHFFFAOYSA-M potassium thiocyanate Chemical compound [K+].[S-]C#N ZNNZYHKDIALBAK-UHFFFAOYSA-M 0.000 description 8
229940088594 vitamin Drugs 0.000 description 8
239000011782 vitamin Substances 0.000 description 8
235000013343 vitamin Nutrition 0.000 description 8
229930003231 vitamin Natural products 0.000 description 8
HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 7
102000013566 Plasminogen Human genes 0.000 description 7
108010051456 Plasminogen Proteins 0.000 description 7
VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 7
230000015572 biosynthetic process Effects 0.000 description 7
238000004113 cell culture Methods 0.000 description 7
SUYVUBYJARFZHO-RRKCRQDMSA-N dATP Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@H]1C[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 SUYVUBYJARFZHO-RRKCRQDMSA-N 0.000 description 7
SUYVUBYJARFZHO-UHFFFAOYSA-N dATP Natural products C1=NC=2C(N)=NC=NC=2N1C1CC(O)C(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 SUYVUBYJARFZHO-UHFFFAOYSA-N 0.000 description 7
ZMMJGEGLRURXTF-UHFFFAOYSA-N ethidium bromide Chemical compound [Br-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CC)=C1C1=CC=CC=C1 ZMMJGEGLRURXTF-UHFFFAOYSA-N 0.000 description 7
229960005542 ethidium bromide Drugs 0.000 description 7
239000000284 extract Substances 0.000 description 7
230000002068 genetic effect Effects 0.000 description 7
238000004255 ion exchange chromatography Methods 0.000 description 7
230000037361 pathway Effects 0.000 description 7
239000000825 pharmaceutical preparation Substances 0.000 description 7
229940012957 plasmin Drugs 0.000 description 7
239000001632 sodium acetate Substances 0.000 description 7
235000017281 sodium acetate Nutrition 0.000 description 7
239000000126 substance Substances 0.000 description 7
230000001629 suppression Effects 0.000 description 7
239000000725 suspension Substances 0.000 description 7
230000002103 transcriptional effect Effects 0.000 description 7
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
108091032973 (ribonucleotides)n+m Proteins 0.000 description 6
108010039627 Aprotinin Proteins 0.000 description 6
102100031780 Endonuclease Human genes 0.000 description 6
DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 6
101710163270 Nuclease Proteins 0.000 description 6
229930006000 Sucrose Natural products 0.000 description 6
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 6
102000003990 Urokinase-type plasminogen activator Human genes 0.000 description 6
108090000435 Urokinase-type plasminogen activator Proteins 0.000 description 6
239000013611 chromosomal DNA Substances 0.000 description 6
238000012217 deletion Methods 0.000 description 6
230000037430 deletion Effects 0.000 description 6
239000006167 equilibration buffer Substances 0.000 description 6
238000012869 ethanol precipitation Methods 0.000 description 6
239000001963 growth medium Substances 0.000 description 6
244000005700 microbiome Species 0.000 description 6
239000008188 pellet Substances 0.000 description 6
230000001105 regulatory effect Effects 0.000 description 6
230000003248 secreting effect Effects 0.000 description 6
239000005720 sucrose Substances 0.000 description 6
229960005356 urokinase Drugs 0.000 description 6
102000002260 Alkaline Phosphatase Human genes 0.000 description 5
108020004774 Alkaline Phosphatase Proteins 0.000 description 5
108010042407 Endonucleases Proteins 0.000 description 5
ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 5
108091000080 Phosphotransferase Proteins 0.000 description 5
208000007536 Thrombosis Diseases 0.000 description 5
239000011324 bead Substances 0.000 description 5
230000003115 biocidal effect Effects 0.000 description 5
244000309466 calf Species 0.000 description 5
229940041514 candida albicans extract Drugs 0.000 description 5
239000003795 chemical substances by application Substances 0.000 description 5
NHVNXKFIZYSCEB-XLPZGREQSA-N dTTP Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)C1 NHVNXKFIZYSCEB-XLPZGREQSA-N 0.000 description 5
239000003599 detergent Substances 0.000 description 5
238000005516 engineering process Methods 0.000 description 5
239000003527 fibrinolytic agent Substances 0.000 description 5
230000006870 function Effects 0.000 description 5
238000009396 hybridization Methods 0.000 description 5
ZPNFWUPYTFPOJU-LPYSRVMUSA-N iniprol Chemical compound C([C@H]1C(=O)NCC(=O)NCC(=O)N[C@H]2CSSC[C@H]3C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(N[C@H](C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC=4C=CC=CC=4)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC=4C=CC=CC=4)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC2=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H]2N(CCC2)C(=O)[C@@H](N)CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N2[C@@H](CCC2)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N2[C@@H](CCC2)C(=O)N3)C(=O)NCC(=O)NCC(=O)N[C@@H](C)C(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@H](C(=O)N1)C(C)C)[C@@H](C)O)[C@@H](C)CC)=O)[C@@H](C)CC)C1=CC=C(O)C=C1 ZPNFWUPYTFPOJU-LPYSRVMUSA-N 0.000 description 5
229910052816 inorganic phosphate Inorganic materials 0.000 description 5
239000010410 layer Substances 0.000 description 5
210000004962 mammalian cell Anatomy 0.000 description 5
239000012528 membrane Substances 0.000 description 5
102000020233 phosphotransferase Human genes 0.000 description 5
238000012163 sequencing technique Methods 0.000 description 5
239000007787 solid Substances 0.000 description 5
239000012138 yeast extract Substances 0.000 description 5
DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 5
102000053602 DNA Human genes 0.000 description 4
108060002716 Exonuclease Proteins 0.000 description 4
101001074244 Homo sapiens Glycophorin-A Proteins 0.000 description 4
108091034117 Oligonucleotide Proteins 0.000 description 4
239000002202 Polyethylene glycol Substances 0.000 description 4
229920005654 Sephadex Polymers 0.000 description 4
239000012507 Sephadex™ Substances 0.000 description 4
238000012300 Sequence Analysis Methods 0.000 description 4
239000008051 TBE buffer Substances 0.000 description 4
238000002835 absorbance Methods 0.000 description 4
239000004480 active ingredient Substances 0.000 description 4
235000011130 ammonium sulphate Nutrition 0.000 description 4
239000005018 casein Substances 0.000 description 4
BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 4
235000021240 caseins Nutrition 0.000 description 4
YPHMISFOHDHNIV-FSZOTQKASA-N cycloheximide Chemical compound C1[C@@H](C)C[C@H](C)C(=O)[C@@H]1[C@H](O)CC1CC(=O)NC(=O)C1 YPHMISFOHDHNIV-FSZOTQKASA-N 0.000 description 4
HAAZLUGHYHWQIW-KVQBGUIXSA-N dGTP Chemical compound C1=NC=2C(=O)NC(N)=NC=2N1[C@H]1C[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 HAAZLUGHYHWQIW-KVQBGUIXSA-N 0.000 description 4
239000008367 deionised water Substances 0.000 description 4
229910021641 deionized water Inorganic materials 0.000 description 4
238000000502 dialysis Methods 0.000 description 4
238000001962 electrophoresis Methods 0.000 description 4
102000013165 exonuclease Human genes 0.000 description 4
238000002474 experimental method Methods 0.000 description 4
239000011521 glass Substances 0.000 description 4
108020004445 glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 description 4
229960002885 histidine Drugs 0.000 description 4
102000044241 human GYPA Human genes 0.000 description 4
239000002054 inoculum Substances 0.000 description 4
230000035772 mutation Effects 0.000 description 4
230000036961 partial effect Effects 0.000 description 4
229920001223 polyethylene glycol Polymers 0.000 description 4
235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 4
229920000136 polysorbate Polymers 0.000 description 4
229920000053 polysorbate 80 Polymers 0.000 description 4
SCVFZCLFOSHCOH-UHFFFAOYSA-M potassium acetate Chemical compound [K+].CC([O-])=O SCVFZCLFOSHCOH-UHFFFAOYSA-M 0.000 description 4
239000002243 precursor Substances 0.000 description 4
239000011734 sodium Substances 0.000 description 4
238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 4
239000000758 substrate Substances 0.000 description 4
239000006228 supernatant Substances 0.000 description 4
230000035897 transcription Effects 0.000 description 4
238000013518 transcription Methods 0.000 description 4
238000011144 upstream manufacturing Methods 0.000 description 4
238000005406 washing Methods 0.000 description 4
108020005065 3' Flanking Region Proteins 0.000 description 3
KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 3
108091003079 Bovine Serum Albumin Proteins 0.000 description 3
FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 3
102000004594 DNA Polymerase I Human genes 0.000 description 3
108010017826 DNA Polymerase I Proteins 0.000 description 3
108010054576 Deoxyribonuclease EcoRI Proteins 0.000 description 3
108010049003 Fibrinogen Proteins 0.000 description 3
102000008946 Fibrinogen Human genes 0.000 description 3
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
208000032843 Hemorrhage Diseases 0.000 description 3
101000605403 Homo sapiens Plasminogen Proteins 0.000 description 3
102100024319 Intestinal-type alkaline phosphatase Human genes 0.000 description 3
101710184243 Intestinal-type alkaline phosphatase Proteins 0.000 description 3
239000006142 Luria-Bertani Agar Substances 0.000 description 3
108010021757 Polynucleotide 5'-Hydroxyl-Kinase Proteins 0.000 description 3
102000008422 Polynucleotide 5'-hydroxyl-kinase Human genes 0.000 description 3
108091034057 RNA (poly(A)) Proteins 0.000 description 3
108020004511 Recombinant DNA Proteins 0.000 description 3
108010023197 Streptokinase Proteins 0.000 description 3
208000037065 Subacute sclerosing leukoencephalitis Diseases 0.000 description 3
206010042297 Subacute sclerosing panencephalitis Diseases 0.000 description 3
JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 3
230000009471 action Effects 0.000 description 3
BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 3
229910052921 ammonium sulfate Inorganic materials 0.000 description 3
230000003321 amplification Effects 0.000 description 3
239000003242 anti bacterial agent Substances 0.000 description 3
239000008346 aqueous phase Substances 0.000 description 3
229960001230 asparagine Drugs 0.000 description 3
238000003556 assay Methods 0.000 description 3
PXXJHWLDUBFPOL-UHFFFAOYSA-N benzamidine Chemical compound NC(=N)C1=CC=CC=C1 PXXJHWLDUBFPOL-UHFFFAOYSA-N 0.000 description 3
SXTGIAYWYXVNLT-NRFANRHFSA-N benzyl n-[2-[[2-[[(2s)-5-(diaminomethylideneamino)-1-[(4-methyl-2-oxochromen-7-yl)amino]-1-oxopentan-2-yl]amino]-2-oxoethyl]amino]-2-oxoethyl]carbamate Chemical compound N([C@@H](CCCNC(N)=N)C(=O)NC1=CC=2OC(=O)C=C(C=2C=C1)C)C(=O)CNC(=O)CNC(=O)OCC1=CC=CC=C1 SXTGIAYWYXVNLT-NRFANRHFSA-N 0.000 description 3
WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 3
239000004327 boric acid Substances 0.000 description 3
239000007853 buffer solution Substances 0.000 description 3
230000003196 chaotropic effect Effects 0.000 description 3
239000003153 chemical reaction reagent Substances 0.000 description 3
MUCZHBLJLSDCSD-UHFFFAOYSA-N diisopropyl fluorophosphate Chemical compound CC(C)OP(F)(=O)OC(C)C MUCZHBLJLSDCSD-UHFFFAOYSA-N 0.000 description 3
LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 3
DNJIEGIFACGWOD-UHFFFAOYSA-N ethyl mercaptane Natural products CCS DNJIEGIFACGWOD-UHFFFAOYSA-N 0.000 description 3
239000000208 fibrin degradation product Substances 0.000 description 3
229940012952 fibrinogen Drugs 0.000 description 3
229960005051 fluostigmine Drugs 0.000 description 3
238000001502 gel electrophoresis Methods 0.000 description 3
102000006602 glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 description 3
230000034659 glycolysis Effects 0.000 description 3
238000004128 high performance liquid chromatography Methods 0.000 description 3
238000000338 in vitro Methods 0.000 description 3
230000004807 localization Effects 0.000 description 3
239000012139 lysis buffer Substances 0.000 description 3
230000007246 mechanism Effects 0.000 description 3
238000003199 nucleic acid amplification method Methods 0.000 description 3
108020004707 nucleic acids Proteins 0.000 description 3
102000039446 nucleic acids Human genes 0.000 description 3
150000007523 nucleic acids Chemical class 0.000 description 3
210000000287 oocyte Anatomy 0.000 description 3
210000001322 periplasm Anatomy 0.000 description 3
230000000144 pharmacologic effect Effects 0.000 description 3
230000033885 plasminogen activation Effects 0.000 description 3
230000002797 proteolythic effect Effects 0.000 description 3
230000006798 recombination Effects 0.000 description 3
238000005215 recombination Methods 0.000 description 3
230000003362 replicative effect Effects 0.000 description 3
230000002441 reversible effect Effects 0.000 description 3
230000028327 secretion Effects 0.000 description 3
238000000926 separation method Methods 0.000 description 3
239000000600 sorbitol Substances 0.000 description 3
230000001954 sterilising effect Effects 0.000 description 3
238000004659 sterilization and disinfection Methods 0.000 description 3
229960005202 streptokinase Drugs 0.000 description 3
238000003786 synthesis reaction Methods 0.000 description 3
230000002537 thrombolytic effect Effects 0.000 description 3
230000001131 transforming effect Effects 0.000 description 3
YNJBWRMUSHSURL-UHFFFAOYSA-N trichloroacetic acid Chemical compound OC(=O)C(Cl)(Cl)Cl YNJBWRMUSHSURL-UHFFFAOYSA-N 0.000 description 3
239000011800 void material Substances 0.000 description 3
OSJPPGNTCRNQQC-UWTATZPHSA-N 3-phospho-D-glyceric acid Chemical compound OC(=O)[C@H](O)COP(O)(O)=O OSJPPGNTCRNQQC-UWTATZPHSA-N 0.000 description 2
ALYNCZNDIQEVRV-UHFFFAOYSA-N 4-aminobenzoic acid Chemical compound NC1=CC=C(C(O)=O)C=C1 ALYNCZNDIQEVRV-UHFFFAOYSA-N 0.000 description 2
GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 2
201000001320 Atherosclerosis Diseases 0.000 description 2
108010023063 Bacto-peptone Proteins 0.000 description 2
FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
108010008286 DNA nucleotidylexotransferase Proteins 0.000 description 2
102100029764 DNA-directed DNA/RNA polymerase mu Human genes 0.000 description 2
208000005189 Embolism Diseases 0.000 description 2
102000010911 Enzyme Precursors Human genes 0.000 description 2
108010062466 Enzyme Precursors Proteins 0.000 description 2
241000219769 Erythrina latissima Species 0.000 description 2
241000701959 Escherichia virus Lambda Species 0.000 description 2
241000206602 Eukaryota Species 0.000 description 2
102000005731 Glucose-6-phosphate isomerase Human genes 0.000 description 2
108010070600 Glucose-6-phosphate isomerase Proteins 0.000 description 2
108010056771 Glucosidases Proteins 0.000 description 2
102000004366 Glucosidases Human genes 0.000 description 2
101150009006 HIS3 gene Proteins 0.000 description 2
XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
102000003960 Ligases Human genes 0.000 description 2
108090000364 Ligases Proteins 0.000 description 2
NPBGTPKLVJEOBE-IUCAKERBSA-N Lys-Arg Chemical group NCCCC[C@H](N)C(=O)N[C@H](C(O)=O)CCCNC(N)=N NPBGTPKLVJEOBE-IUCAKERBSA-N 0.000 description 2
239000007993 MOPS buffer Substances 0.000 description 2
229930195725 Mannitol Natural products 0.000 description 2
PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 2
-1 PGK Proteins 0.000 description 2
101150003126 PHO3 gene Proteins 0.000 description 2
102000035195 Peptidases Human genes 0.000 description 2
108091005804 Peptidases Proteins 0.000 description 2
206010050902 Postoperative thrombosis Diseases 0.000 description 2
239000004365 Protease Substances 0.000 description 2
108010092799 RNA-directed DNA polymerase Proteins 0.000 description 2
101100394989 Rhodopseudomonas palustris (strain ATCC BAA-98 / CGA009) hisI gene Proteins 0.000 description 2
AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 description 2
PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 2
208000001435 Thromboembolism Diseases 0.000 description 2
206010047249 Venous thrombosis Diseases 0.000 description 2
IXKSXJFAGXLQOQ-XISFHERQSA-N WHWLQLKPGQPMY Chemical compound C([C@@H](C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(O)=O)NC(=O)[C@@H](N)CC=1C2=CC=CC=C2NC=1)C1=CNC=N1 IXKSXJFAGXLQOQ-XISFHERQSA-N 0.000 description 2
ZKHQWZAMYRWXGA-KNYAHOBESA-N [[(2r,3s,4r,5r)-5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl] dihydroxyphosphoryl hydrogen phosphate Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)O[32P](O)(O)=O)[C@@H](O)[C@H]1O ZKHQWZAMYRWXGA-KNYAHOBESA-N 0.000 description 2
239000002253 acid Substances 0.000 description 2
230000004913 activation Effects 0.000 description 2
230000001464 adherent effect Effects 0.000 description 2
239000000853 adhesive Substances 0.000 description 2
230000001070 adhesive effect Effects 0.000 description 2
230000003024 amidolytic effect Effects 0.000 description 2
229940088710 antibiotic agent Drugs 0.000 description 2
239000003146 anticoagulant agent Substances 0.000 description 2
KGBXLFKZBHKPEV-UHFFFAOYSA-N boric acid Chemical compound OB(O)O KGBXLFKZBHKPEV-UHFFFAOYSA-N 0.000 description 2
229940098773 bovine serum albumin Drugs 0.000 description 2
150000001720 carbohydrates Chemical group 0.000 description 2
206010008118 cerebral infarction Diseases 0.000 description 2
208000026106 cerebrovascular disease Diseases 0.000 description 2
230000008859 change Effects 0.000 description 2
BKHZIBWEHPHYAI-UHFFFAOYSA-N chloroform;3-methylbutan-1-ol Chemical compound ClC(Cl)Cl.CC(C)CCO BKHZIBWEHPHYAI-UHFFFAOYSA-N 0.000 description 2
238000011097 chromatography purification Methods 0.000 description 2
230000000295 complement effect Effects 0.000 description 2
ATDGTVJJHBUTRL-UHFFFAOYSA-N cyanogen bromide Chemical compound BrC#N ATDGTVJJHBUTRL-UHFFFAOYSA-N 0.000 description 2
238000013461 design Methods 0.000 description 2
206010012601 diabetes mellitus Diseases 0.000 description 2
230000008030 elimination Effects 0.000 description 2
238000003379 elimination reaction Methods 0.000 description 2
239000002158 endotoxin Substances 0.000 description 2
230000001036 exonucleolytic effect Effects 0.000 description 2
238000007421 fluorometric assay Methods 0.000 description 2
OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 2
238000005194 fractionation Methods 0.000 description 2
235000001727 glucose Nutrition 0.000 description 2
239000012145 high-salt buffer Substances 0.000 description 2
230000006872 improvement Effects 0.000 description 2
230000006698 induction Effects 0.000 description 2
230000000977 initiatory effect Effects 0.000 description 2
CDAISMWEOUEBRE-GPIVLXJGSA-N inositol Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@@H]1O CDAISMWEOUEBRE-GPIVLXJGSA-N 0.000 description 2
238000003780 insertion Methods 0.000 description 2
230000037431 insertion Effects 0.000 description 2
238000009830 intercalation Methods 0.000 description 2
230000002687 intercalation Effects 0.000 description 2
239000000543 intermediate Substances 0.000 description 2
210000000936 intestine Anatomy 0.000 description 2
238000005304 joining Methods 0.000 description 2
239000008101 lactose Substances 0.000 description 2
239000011777 magnesium Substances 0.000 description 2
UEGPKNKPLBYCNK-UHFFFAOYSA-L magnesium acetate Chemical compound [Mg+2].CC([O-])=O.CC([O-])=O UEGPKNKPLBYCNK-UHFFFAOYSA-L 0.000 description 2
239000011654 magnesium acetate Substances 0.000 description 2
235000011285 magnesium acetate Nutrition 0.000 description 2
229940069446 magnesium acetate Drugs 0.000 description 2
239000000594 mannitol Substances 0.000 description 2
235000010355 mannitol Nutrition 0.000 description 2
239000000463 material Substances 0.000 description 2
238000010369 molecular cloning Methods 0.000 description 2
150000004682 monohydrates Chemical class 0.000 description 2
230000002107 myocardial effect Effects 0.000 description 2
208000010125 myocardial infarction Diseases 0.000 description 2
239000000546 pharmaceutical excipient Substances 0.000 description 2
239000012071 phase Substances 0.000 description 2
230000026731 phosphorylation Effects 0.000 description 2
238000006366 phosphorylation reaction Methods 0.000 description 2
238000013492 plasmid preparation Methods 0.000 description 2
238000007747 plating Methods 0.000 description 2
235000011056 potassium acetate Nutrition 0.000 description 2
239000002244 precipitate Substances 0.000 description 2
108090000765 processed proteins & peptides Proteins 0.000 description 2
102000004196 processed proteins & peptides Human genes 0.000 description 2
210000001236 prokaryotic cell Anatomy 0.000 description 2
238000011084 recovery Methods 0.000 description 2
229920006395 saturated elastomer Polymers 0.000 description 2
CDAISMWEOUEBRE-UHFFFAOYSA-N scyllo-inosotol Natural products OC1C(O)C(O)C(O)C(O)C1O CDAISMWEOUEBRE-UHFFFAOYSA-N 0.000 description 2
230000011664 signaling Effects 0.000 description 2
238000010186 staining Methods 0.000 description 2
230000000638 stimulation Effects 0.000 description 2
238000003756 stirring Methods 0.000 description 2
239000011550 stock solution Substances 0.000 description 2
201000005060 thrombophlebitis Diseases 0.000 description 2
238000010361 transduction Methods 0.000 description 2
230000026683 transduction Effects 0.000 description 2
238000000844 transformation Methods 0.000 description 2
230000014621 translational initiation Effects 0.000 description 2
239000012137 tryptone Substances 0.000 description 2
238000009281 ultraviolet germicidal irradiation Methods 0.000 description 2
208000019553 vascular disease Diseases 0.000 description 2
150000003722 vitamin derivatives Chemical class 0.000 description 2
239000007222 ypd medium Substances 0.000 description 2
VHJLVAABSRFDPM-UHFFFAOYSA-N 1,4-dithiothreitol Chemical compound SCC(O)C(O)CS VHJLVAABSRFDPM-UHFFFAOYSA-N 0.000 description 1
OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
QHQZEEGNGSZBOL-UHFFFAOYSA-N 2-(aminomethyl)-2-(hydroxymethyl)propane-1,3-diol Chemical compound NCC(CO)(CO)CO QHQZEEGNGSZBOL-UHFFFAOYSA-N 0.000 description 1
JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
IVLXQGJVBGMLRR-UHFFFAOYSA-N 2-aminoacetic acid;hydron;chloride Chemical compound Cl.NCC(O)=O IVLXQGJVBGMLRR-UHFFFAOYSA-N 0.000 description 1
125000000954 2-hydroxyethyl group Chemical group [H]C([*])([H])C([H])([H])O[H] 0.000 description 1
LHYQAEFVHIZFLR-UHFFFAOYSA-L 4-(4-diazonio-3-methoxyphenyl)-2-methoxybenzenediazonium;dichloride Chemical compound [Cl-].[Cl-].C1=C([N+]#N)C(OC)=CC(C=2C=C(OC)C([N+]#N)=CC=2)=C1 LHYQAEFVHIZFLR-UHFFFAOYSA-L 0.000 description 1
101710163881 5,6-dihydroxyindole-2-carboxylic acid oxidase Proteins 0.000 description 1
QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
108010088751 Albumins Proteins 0.000 description 1
102000009027 Albumins Human genes 0.000 description 1
239000004475 Arginine Substances 0.000 description 1
241000894006 Bacteria Species 0.000 description 1
108010077805 Bacterial Proteins Proteins 0.000 description 1
WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
101000583080 Bunodosoma granuliferum Delta-actitoxin-Bgr2a Proteins 0.000 description 1
101000583086 Bunodosoma granuliferum Delta-actitoxin-Bgr2b Proteins 0.000 description 1
101150111062 C gene Proteins 0.000 description 1
108010072454 CTGCAG-specific type II deoxyribonucleases Proteins 0.000 description 1
101100148606 Caenorhabditis elegans pst-1 gene Proteins 0.000 description 1
241000222120 Candida <Saccharomycetales> Species 0.000 description 1
108020004705 Codon Proteins 0.000 description 1
101710117667 Constitutive acid phosphatase Proteins 0.000 description 1
AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 description 1
108010066072 DNA modification methylase EcoRI Proteins 0.000 description 1
108010005054 Deoxyribonuclease BamHI Proteins 0.000 description 1
229920002307 Dextran Polymers 0.000 description 1
241001397104 Dima Species 0.000 description 1
239000004129 EU approved improving agent Substances 0.000 description 1
102000004533 Endonucleases Human genes 0.000 description 1
101000798869 Escherichia phage Mu DDE-recombinase A Proteins 0.000 description 1
108091092566 Extrachromosomal DNA Proteins 0.000 description 1
201000008808 Fibrosarcoma Diseases 0.000 description 1
229920001917 Ficoll Polymers 0.000 description 1
230000005526 G1 to G0 transition Effects 0.000 description 1
241000237858 Gastropoda Species 0.000 description 1
108700007698 Genetic Terminator Regions Proteins 0.000 description 1
108010021582 Glucokinase Proteins 0.000 description 1
102100036716 Glycosylphosphatidylinositol anchor attachment 1 protein Human genes 0.000 description 1
241001446459 Heia Species 0.000 description 1
SQUHHTBVTRBESD-UHFFFAOYSA-N Hexa-Ac-myo-Inositol Natural products CC(=O)OC1C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C1OC(C)=O SQUHHTBVTRBESD-UHFFFAOYSA-N 0.000 description 1
102000005548 Hexokinase Human genes 0.000 description 1
108700040460 Hexokinases Proteins 0.000 description 1
241000282412 Homo Species 0.000 description 1
101001072432 Homo sapiens Glycosylphosphatidylinositol anchor attachment 1 protein Proteins 0.000 description 1
101000801481 Homo sapiens Tissue-type plasminogen activator Proteins 0.000 description 1
206010020751 Hypersensitivity Diseases 0.000 description 1
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
239000004472 Lysine Substances 0.000 description 1
FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
PWHULOQIROXLJO-UHFFFAOYSA-N Manganese Chemical compound [Mn] PWHULOQIROXLJO-UHFFFAOYSA-N 0.000 description 1
WEDDFMCSUNNZJR-WDSKDSINSA-N Met-Ser Chemical compound CSCC[C@H](N)C(=O)N[C@@H](CO)C(O)=O WEDDFMCSUNNZJR-WDSKDSINSA-N 0.000 description 1
108060004795 Methyltransferase Proteins 0.000 description 1
108010014251 Muramidase Proteins 0.000 description 1
102000016943 Muramidase Human genes 0.000 description 1
108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 description 1
OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 description 1
229910002651 NO3 Inorganic materials 0.000 description 1
NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
239000000020 Nitrocellulose Substances 0.000 description 1
241000283973 Oryctolagus cuniculus Species 0.000 description 1
101100508851 Oryza sativa subsp. japonica CIN6 gene Proteins 0.000 description 1
229910019142 PO4 Inorganic materials 0.000 description 1
239000001888 Peptone Substances 0.000 description 1
108010080698 Peptones Proteins 0.000 description 1
102000001105 Phosphofructokinases Human genes 0.000 description 1
108010069341 Phosphofructokinases Proteins 0.000 description 1
102000012288 Phosphopyruvate Hydratase Human genes 0.000 description 1
108010022181 Phosphopyruvate Hydratase Proteins 0.000 description 1
239000004698 Polyethylene Substances 0.000 description 1
229920002873 Polyethylenimine Polymers 0.000 description 1
239000004743 Polypropylene Substances 0.000 description 1
208000035965 Postoperative Complications Diseases 0.000 description 1
ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
108010011939 Pyruvate Decarboxylase Proteins 0.000 description 1
102000013009 Pyruvate Kinase Human genes 0.000 description 1
108020005115 Pyruvate Kinase Proteins 0.000 description 1
108020005091 Replication Origin Proteins 0.000 description 1
101710167911 Repressible acid phosphatase Proteins 0.000 description 1
241000235346 Schizosaccharomyces Species 0.000 description 1
102000012479 Serine Proteases Human genes 0.000 description 1
108010022999 Serine Proteases Proteins 0.000 description 1
102100032491 Serine protease 1 Human genes 0.000 description 1
108091081024 Start codon Proteins 0.000 description 1
101000895926 Streptomyces plicatus Endo-beta-N-acetylglucosaminidase H Proteins 0.000 description 1
208000006011 Stroke Diseases 0.000 description 1
QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
101150006914 TRP1 gene Proteins 0.000 description 1
108090000190 Thrombin Proteins 0.000 description 1
102000005924 Triose-Phosphate Isomerase Human genes 0.000 description 1
108700015934 Triose-phosphate isomerases Proteins 0.000 description 1
208000026487 Triploidy Diseases 0.000 description 1
108020005202 Viral DNA Proteins 0.000 description 1
108091060592 XDNA Proteins 0.000 description 1
240000008042 Zea mays Species 0.000 description 1
235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
235000002017 Zea mays subsp mays Nutrition 0.000 description 1
HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
239000008351 acetate buffer Substances 0.000 description 1
238000003916 acid precipitation Methods 0.000 description 1
150000007513 acids Chemical class 0.000 description 1
239000012190 activator Substances 0.000 description 1
239000002671 adjuvant Substances 0.000 description 1
238000005273 aeration Methods 0.000 description 1
238000000246 agarose gel electrophoresis Methods 0.000 description 1
235000001014 amino acid Nutrition 0.000 description 1
229960004050 aminobenzoic acid Drugs 0.000 description 1
229940126575 aminoglycoside Drugs 0.000 description 1
235000019270 ammonium chloride Nutrition 0.000 description 1
150000003863 ammonium salts Chemical class 0.000 description 1
239000001166 ammonium sulphate Substances 0.000 description 1
230000003698 anagen phase Effects 0.000 description 1
210000004102 animal cell Anatomy 0.000 description 1
229960004405 aprotinin Drugs 0.000 description 1
239000007864 aqueous solution Substances 0.000 description 1
239000007900 aqueous suspension Substances 0.000 description 1
ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
230000009286 beneficial effect Effects 0.000 description 1
230000008901 benefit Effects 0.000 description 1
YNUUYYYGCIXHFI-UHFFFAOYSA-N benzoic acid;1-nitro-1-phenylguanidine Chemical compound OC(=O)C1=CC=CC=C1.NC(=N)N([N+]([O-])=O)C1=CC=CC=C1 YNUUYYYGCIXHFI-UHFFFAOYSA-N 0.000 description 1
108010051210 beta-Fructofuranosidase Proteins 0.000 description 1
GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
239000003139 biocide Substances 0.000 description 1
230000001851 biosynthetic effect Effects 0.000 description 1
229960002685 biotin Drugs 0.000 description 1
YBJHBAHKTGYVGT-ZKWXMUAHSA-N biotin Natural products N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 1
235000020958 biotin Nutrition 0.000 description 1
239000011616 biotin Substances 0.000 description 1
230000000740 bleeding effect Effects 0.000 description 1
210000004369 blood Anatomy 0.000 description 1
239000008280 blood Substances 0.000 description 1
GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
229910052794 bromium Inorganic materials 0.000 description 1
238000010804 cDNA synthesis Methods 0.000 description 1
235000015115 caffè latte Nutrition 0.000 description 1
FAPWYRCQGJNNSJ-UBKPKTQASA-L calcium D-pantothenic acid Chemical compound [Ca+2].OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O.OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O FAPWYRCQGJNNSJ-UBKPKTQASA-L 0.000 description 1
230000000711 cancerogenic effect Effects 0.000 description 1
235000014633 carbohydrates Nutrition 0.000 description 1
150000004649 carbonic acid derivatives Chemical class 0.000 description 1
231100000315 carcinogenic Toxicity 0.000 description 1
230000003197 catalytic effect Effects 0.000 description 1
230000006037 cell lysis Effects 0.000 description 1
210000000170 cell membrane Anatomy 0.000 description 1
239000013553 cell monolayer Substances 0.000 description 1
239000006285 cell suspension Substances 0.000 description 1
239000013043 chemical agent Substances 0.000 description 1
229960005091 chloramphenicol Drugs 0.000 description 1
WIIZWVCIJKGZOK-RKDXNWHRSA-N chloramphenicol Chemical compound ClC(Cl)C(=O)N[C@H](CO)[C@H](O)C1=CC=C([N+]([O-])=O)C=C1 WIIZWVCIJKGZOK-RKDXNWHRSA-N 0.000 description 1
150000001805 chlorine compounds Chemical class 0.000 description 1
ZYWFEOZQIUMEGL-UHFFFAOYSA-N chloroform;3-methylbutan-1-ol;phenol Chemical compound ClC(Cl)Cl.CC(C)CCO.OC1=CC=CC=C1 ZYWFEOZQIUMEGL-UHFFFAOYSA-N 0.000 description 1
239000013599 cloning vector Substances 0.000 description 1
230000015271 coagulation Effects 0.000 description 1
238000005345 coagulation Methods 0.000 description 1
150000001875 compounds Chemical class 0.000 description 1
230000001276 controlling effect Effects 0.000 description 1
238000007796 conventional method Methods 0.000 description 1
238000001816 cooling Methods 0.000 description 1
235000005822 corn Nutrition 0.000 description 1
239000013601 cosmid vector Substances 0.000 description 1
230000008878 coupling Effects 0.000 description 1
238000010168 coupling process Methods 0.000 description 1
238000005859 coupling reaction Methods 0.000 description 1
230000009089 cytolysis Effects 0.000 description 1
210000000805 cytoplasm Anatomy 0.000 description 1
230000006378 damage Effects 0.000 description 1
230000003247 decreasing effect Effects 0.000 description 1
230000006735 deficit Effects 0.000 description 1
239000007857 degradation product Substances 0.000 description 1
238000004925 denaturation Methods 0.000 description 1
230000036425 denaturation Effects 0.000 description 1
230000001419 dependent effect Effects 0.000 description 1
230000030609 dephosphorylation Effects 0.000 description 1
238000006209 dephosphorylation reaction Methods 0.000 description 1
238000011161 development Methods 0.000 description 1
230000018109 developmental process Effects 0.000 description 1
238000009792 diffusion process Methods 0.000 description 1
201000010099 disease Diseases 0.000 description 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
238000009826 distribution Methods 0.000 description 1
VHJLVAABSRFDPM-QWWZWVQMSA-N dithiothreitol Chemical compound SC[C@@H](O)[C@H](O)CS VHJLVAABSRFDPM-QWWZWVQMSA-N 0.000 description 1
239000003937 drug carrier Substances 0.000 description 1
238000010828 elution Methods 0.000 description 1
239000003995 emulsifying agent Substances 0.000 description 1
230000006862 enzymatic digestion Effects 0.000 description 1
238000011067 equilibration Methods 0.000 description 1
230000008029 eradication Effects 0.000 description 1
210000003527 eukaryotic cell Anatomy 0.000 description 1
230000029142 excretion Effects 0.000 description 1
239000012091 fetal bovine serum Substances 0.000 description 1
238000001914 filtration Methods 0.000 description 1
229960000304 folic acid Drugs 0.000 description 1
235000019152 folic acid Nutrition 0.000 description 1
239000011724 folic acid Substances 0.000 description 1
238000007710 freezing Methods 0.000 description 1
230000008014 freezing Effects 0.000 description 1
235000011389 fruit/vegetable juice Nutrition 0.000 description 1
230000004927 fusion Effects 0.000 description 1
229960001031 glucose Drugs 0.000 description 1
108010087005 glusulase Proteins 0.000 description 1
230000036252 glycation Effects 0.000 description 1
230000002414 glycolytic effect Effects 0.000 description 1
238000003306 harvesting Methods 0.000 description 1
229910001385 heavy metal Inorganic materials 0.000 description 1
HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
229920001519 homopolymer Polymers 0.000 description 1
210000005260 human cell Anatomy 0.000 description 1
230000001900 immune effect Effects 0.000 description 1
238000007901 in situ hybridization Methods 0.000 description 1
238000003017 in situ immunoassay Methods 0.000 description 1
238000001727 in vivo Methods 0.000 description 1
230000002779 inactivation Effects 0.000 description 1
230000036512 infertility Effects 0.000 description 1
239000003978 infusion fluid Substances 0.000 description 1
239000004615 ingredient Substances 0.000 description 1
229960000367 inositol Drugs 0.000 description 1
230000010354 integration Effects 0.000 description 1
230000003993 interaction Effects 0.000 description 1
230000002452 interceptive effect Effects 0.000 description 1
239000013067 intermediate product Substances 0.000 description 1
230000000968 intestinal effect Effects 0.000 description 1
238000007918 intramuscular administration Methods 0.000 description 1
238000007912 intraperitoneal administration Methods 0.000 description 1
238000001990 intravenous administration Methods 0.000 description 1
239000001573 invertase Substances 0.000 description 1
235000011073 invertase Nutrition 0.000 description 1
238000005342 ion exchange Methods 0.000 description 1
150000002500 ions Chemical class 0.000 description 1
229910052742 iron Inorganic materials 0.000 description 1
230000002147 killing effect Effects 0.000 description 1
235000021374 legumes Nutrition 0.000 description 1
230000003902 lesion Effects 0.000 description 1
230000000670 limiting effect Effects 0.000 description 1
238000011068 loading method Methods 0.000 description 1
210000004698 lymphocyte Anatomy 0.000 description 1
239000006166 lysate Substances 0.000 description 1
239000004325 lysozyme Substances 0.000 description 1
229960000274 lysozyme Drugs 0.000 description 1
235000010335 lysozyme Nutrition 0.000 description 1
229920002521 macromolecule Polymers 0.000 description 1
229910052749 magnesium Inorganic materials 0.000 description 1
238000012423 maintenance Methods 0.000 description 1
230000014759 maintenance of location Effects 0.000 description 1
229910052748 manganese Inorganic materials 0.000 description 1
239000011572 manganese Substances 0.000 description 1
238000013507 mapping Methods 0.000 description 1
230000035800 maturation Effects 0.000 description 1
238000005259 measurement Methods 0.000 description 1
235000013372 meat Nutrition 0.000 description 1
230000001404 mediated effect Effects 0.000 description 1
229930182817 methionine Natural products 0.000 description 1
125000001360 methionine group Chemical group N[C@@H](CCSC)C(=O)* 0.000 description 1
230000011987 methylation Effects 0.000 description 1
238000007069 methylation reaction Methods 0.000 description 1
239000006151 minimal media Substances 0.000 description 1
230000011278 mitosis Effects 0.000 description 1
230000004048 modification Effects 0.000 description 1
238000012986 modification Methods 0.000 description 1
238000004264 monolayer culture Methods 0.000 description 1
230000036438 mutation frequency Effects 0.000 description 1
230000003472 neutralizing effect Effects 0.000 description 1
235000001968 nicotinic acid Nutrition 0.000 description 1
229960003512 nicotinic acid Drugs 0.000 description 1
239000011664 nicotinic acid Substances 0.000 description 1
229920001220 nitrocellulos Polymers 0.000 description 1
230000003287 optical effect Effects 0.000 description 1
230000003204 osmotic effect Effects 0.000 description 1
238000012261 overproduction Methods 0.000 description 1
238000007911 parenteral administration Methods 0.000 description 1
239000013618 particulate matter Substances 0.000 description 1
230000007030 peptide scission Effects 0.000 description 1
235000019319 peptone Nutrition 0.000 description 1
229940127557 pharmaceutical product Drugs 0.000 description 1
DDBREPKUVSBGFI-UHFFFAOYSA-N phenobarbital Chemical compound C=1C=CC=CC=1C1(CC)C(=O)NC(=O)NC1=O DDBREPKUVSBGFI-UHFFFAOYSA-N 0.000 description 1
239000003016 pheromone Substances 0.000 description 1
235000021317 phosphate Nutrition 0.000 description 1
150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
229920002401 polyacrylamide Polymers 0.000 description 1
238000002264 polyacrylamide gel electrophoresis Methods 0.000 description 1
230000008488 polyadenylation Effects 0.000 description 1
229920001184 polypeptide Polymers 0.000 description 1
229920001155 polypropylene Polymers 0.000 description 1
239000001267 polyvinylpyrrolidone Substances 0.000 description 1
229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
239000011148 porous material Substances 0.000 description 1
239000011591 potassium Substances 0.000 description 1
229910052700 potassium Inorganic materials 0.000 description 1
HJRIWDYVYNNCFY-UHFFFAOYSA-M potassium;dimethylarsinate Chemical compound [K+].C[As](C)([O-])=O HJRIWDYVYNNCFY-UHFFFAOYSA-M 0.000 description 1
230000001376 precipitating effect Effects 0.000 description 1
238000004321 preservation Methods 0.000 description 1
239000003755 preservative agent Substances 0.000 description 1
230000002035 prolonged effect Effects 0.000 description 1
230000000069 prophylactic effect Effects 0.000 description 1
238000000159 protein binding assay Methods 0.000 description 1
230000020978 protein processing Effects 0.000 description 1
ZUFQODAHGAHPFQ-UHFFFAOYSA-N pyridoxine hydrochloride Chemical compound Cl.CC1=NC=C(CO)C(CO)=C1O ZUFQODAHGAHPFQ-UHFFFAOYSA-N 0.000 description 1
229960004172 pyridoxine hydrochloride Drugs 0.000 description 1
235000019171 pyridoxine hydrochloride Nutrition 0.000 description 1
239000011764 pyridoxine hydrochloride Substances 0.000 description 1
239000011541 reaction mixture Substances 0.000 description 1
101150079601 recA gene Proteins 0.000 description 1
230000022532 regulation of transcription, DNA-dependent Effects 0.000 description 1
230000001718 repressive effect Effects 0.000 description 1
238000011160 research Methods 0.000 description 1
230000000284 resting effect Effects 0.000 description 1
235000019192 riboflavin Nutrition 0.000 description 1
229960002477 riboflavin Drugs 0.000 description 1
239000002151 riboflavin Substances 0.000 description 1
238000012216 screening Methods 0.000 description 1
210000002966 serum Anatomy 0.000 description 1
238000001542 size-exclusion chromatography Methods 0.000 description 1
229910052708 sodium Inorganic materials 0.000 description 1
239000001509 sodium citrate Substances 0.000 description 1
FQENQNTWSFEDLI-UHFFFAOYSA-J sodium diphosphate Chemical compound [Na+].[Na+].[Na+].[Na+].[O-]P([O-])(=O)OP([O-])([O-])=O FQENQNTWSFEDLI-UHFFFAOYSA-J 0.000 description 1
239000012064 sodium phosphate buffer Substances 0.000 description 1
229940048086 sodium pyrophosphate Drugs 0.000 description 1
238000002764 solid phase assay Methods 0.000 description 1
125000006850 spacer group Chemical group 0.000 description 1
241000894007 species Species 0.000 description 1
239000003381 stabilizer Substances 0.000 description 1
238000010561 standard procedure Methods 0.000 description 1
238000011146 sterile filtration Methods 0.000 description 1
238000007920 subcutaneous administration Methods 0.000 description 1
238000000856 sucrose gradient centrifugation Methods 0.000 description 1
239000003774 sulfhydryl reagent Substances 0.000 description 1
150000003467 sulfuric acid derivatives Chemical class 0.000 description 1
230000009897 systematic effect Effects 0.000 description 1
238000012360 testing method Methods 0.000 description 1
101150061166 tetR gene Proteins 0.000 description 1
235000019818 tetrasodium diphosphate Nutrition 0.000 description 1
239000001577 tetrasodium phosphonato phosphate Substances 0.000 description 1
229940124597 therapeutic agent Drugs 0.000 description 1
230000001225 therapeutic effect Effects 0.000 description 1
238000002560 therapeutic procedure Methods 0.000 description 1
DPJRMOMPQZCRJU-UHFFFAOYSA-M thiamine hydrochloride Chemical compound Cl.[Cl-].CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N DPJRMOMPQZCRJU-UHFFFAOYSA-M 0.000 description 1
229960000344 thiamine hydrochloride Drugs 0.000 description 1
235000019190 thiamine hydrochloride Nutrition 0.000 description 1
239000011747 thiamine hydrochloride Substances 0.000 description 1
230000009424 thromboembolic effect Effects 0.000 description 1
229960000103 thrombolytic agent Drugs 0.000 description 1
101150010939 tpa gene Proteins 0.000 description 1
230000005026 transcription initiation Effects 0.000 description 1
238000012546 transfer Methods 0.000 description 1
230000032258 transport Effects 0.000 description 1
229940108519 trasylol Drugs 0.000 description 1
150000005691 triesters Chemical class 0.000 description 1
DBPYGJOORSXBMI-UHFFFAOYSA-N trinaphthalen-1-yl phosphate Chemical compound C1=CC=C2C(OP(OC=3C4=CC=CC=C4C=CC=3)(OC=3C4=CC=CC=C4C=CC=3)=O)=CC=CC2=C1 DBPYGJOORSXBMI-UHFFFAOYSA-N 0.000 description 1
PIEPQKCYPFFYMG-UHFFFAOYSA-N tris acetate Chemical compound CC(O)=O.OCC(N)(CO)CO PIEPQKCYPFFYMG-UHFFFAOYSA-N 0.000 description 1
HRXKRNGNAMMEHJ-UHFFFAOYSA-K trisodium citrate Chemical compound [Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O HRXKRNGNAMMEHJ-UHFFFAOYSA-K 0.000 description 1
229940038773 trisodium citrate Drugs 0.000 description 1
GPRLSGONYQIRFK-MNYXATJNSA-N triton Chemical compound [3H+] GPRLSGONYQIRFK-MNYXATJNSA-N 0.000 description 1
210000004881 tumor cell Anatomy 0.000 description 1
108010087967 type I signal peptidase Proteins 0.000 description 1
238000000108 ultra-filtration Methods 0.000 description 1
210000002700 urine Anatomy 0.000 description 1
229910052720 vanadium Inorganic materials 0.000 description 1
238000011179 visual inspection Methods 0.000 description 1
238000005303 weighing Methods 0.000 description 1
239000011701 zinc Substances 0.000 description 1
229910052725 zinc Inorganic materials 0.000 description 1
108010082737 zymolyase Proteins 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
- C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
- C12N9/6424—Serine endopeptidases (3.4.21)
- C12N9/6456—Plasminogen activators
- C12N9/6459—Plasminogen activators t-plasminogen activator (3.4.21.68), i.e. tPA
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/67—General methods for enhancing the expression
- C12N15/69—Increasing the copy number of the vector
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/80—Vectors or expression systems specially adapted for eukaryotic hosts for fungi
- C12N15/81—Vectors or expression systems specially adapted for eukaryotic hosts for fungi for yeasts
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
- C12N15/90—Stable introduction of foreign DNA into chromosome
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/58—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from fungi
- C12N9/60—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from fungi from yeast
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/21—Serine endopeptidases (3.4.21)
- C12Y304/21069—Protein C activated (3.4.21.69)
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence

Landscapes

Life Sciences & Earth Sciences (AREA)
Health & Medical Sciences (AREA)
Genetics & Genomics (AREA)
Engineering & Computer Science (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Zoology (AREA)
Bioinformatics & Cheminformatics (AREA)
Wood Science & Technology (AREA)
General Engineering & Computer Science (AREA)
Biomedical Technology (AREA)
Biotechnology (AREA)
Biochemistry (AREA)
Molecular Biology (AREA)
General Health & Medical Sciences (AREA)
Microbiology (AREA)
Mycology (AREA)
Physics & Mathematics (AREA)
Plant Pathology (AREA)
Biophysics (AREA)
Medicinal Chemistry (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Enzymes And Modification Thereof (AREA)

DD84269628A 1983-11-21 1984-11-19 Verfahren zur herstellung von gewebeplasminogenaktivatoren DD229151A5 (de)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
GB838331045A GB8331045D0 (en)	1983-11-21	1983-11-21	Synthesis of fibrinolytic agents by yeast
GB848423112A GB8423112D0 (en)	1983-11-21	1984-09-13	Synthesis of fibrino lytic agents by yeast

Publications (1)

Publication Number	Publication Date
DD229151A5 true DD229151A5 (de)	1985-10-30

Family

ID=26287024

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DD84269628A DD229151A5 (de)	1983-11-21	1984-11-19	Verfahren zur herstellung von gewebeplasminogenaktivatoren

Country Status (17)

Country	Link
EP (1)	EP0143081B1 (es)
JP (1)	JPS6119489A (es)
KR (1)	KR930002889B1 (es)
AU (1)	AU595478B2 (es)
DD (1)	DD229151A5 (es)
DE (1)	DE3479520D1 (es)
DK (1)	DK164941C (es)
ES (1)	ES8609471A1 (es)
FI (1)	FI86746C (es)
GR (1)	GR80966B (es)
HU (1)	HU201115B (es)
IE (1)	IE57699B1 (es)
IL (1)	IL73568A (es)
NO (1)	NO844618L (es)
NZ (1)	NZ210266A (es)
PH (1)	PH22337A (es)
PT (1)	PT79518B (es)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GR78180B (es) *	1982-04-15	1984-09-26	Genentech Inc
US7138505B1 (en)	1984-01-12	2006-11-21	Novartis Vaccines And Diagnostics, Inc.	Factor VIII:C nucleic acid molecules
WO1986000637A1 (en) *	1984-07-09	1986-01-30	Integrated Genetics, Inc.	Yeast cloning vehicle
DK175327B1 (da) *	1984-10-01	2004-08-23	Integrated Genetics Inc	Replicerbar ekspressionsvektor og rekombinant DNA-molekyle, som indkoder aktiv human livmodervævsplasminogen-aktivator, pattedyrscelle transformeret med vektoren og fremgangsmåde til fremstilling af aktiv human vævsplasminogen-aktivator (TPA)
JPS624233A (ja) *	1985-07-01	1987-01-10	Toyobo Co Ltd	組織性プラスミノ−ゲン活性化因子の製造法
JPS6229975A (ja) *	1985-08-01	1987-02-07	Mitsui Toatsu Chem Inc	粗ｔＰＡの精製法
GB8521496D0 (en) *	1985-08-29	1985-10-02	Ciba Geigy Ag	Repressible yeast promoters
DE3675724D1 (de) *	1985-09-18	1991-01-03	Green Cross Corp	Hefe-promotor und verfahren zur herstellung von heterologen proteinen.
USH2055H1 (en) *	1985-09-20	2002-12-03	Zymogenetics, Inc.	Expression of tissue-type plasminogen activator in bacteria
GB8530631D0 (en)	1985-12-12	1986-01-22	Ciba Geigy Ag	Thrombin inhibitors
MY101203A (en) *	1985-12-12	1991-08-17	Ucp Gen Pharma Ag	Production of thrombin iinhibitors.
US5106741A (en) *	1985-12-20	1992-04-21	The Upjohn Company	Tissue plasminogen activator (TPA) analogs
US4898825A (en) *	1986-05-07	1990-02-06	Mitsui Toatsu Chemicals, Incorporated	Methods for purification of single-chain and double-chain tissue plasminogen activator
ZA872534B (en) *	1986-05-08	1987-11-25	Phillips Petroleum Co	Yeast production of streptokinase
IL82746A (en) *	1986-06-06	1994-10-07	Genentech Inc	Process for producing biologically active tissue-type plasminogen activator
JPS6463378A (en) *	1986-08-11	1989-03-09	Mitsui Toatsu Chemicals	Separation of single stranded tpa and double standard tpa
GB8621118D0 (en) *	1986-09-01	1986-10-08	Whitbread & Co Plc	Stabilised polypeptides
DE3789413T2 (de)	1986-10-03	1994-07-28	Ciba Geigy Ag	Lymphokin-ähnliche Peptide.
PT86162B (pt) *	1986-11-21	1990-11-20	Smithkline Beecham Corp	Expressao de proteina recombinante
ZA879286B (en)	1986-12-16	1988-10-26	Smith Kline Rit	New plasminogen activators
US5149533A (en) *	1987-06-04	1992-09-22	Zymogenetics, Inc.	Modified t-PA with kringle-/replaced by another kringle
US5089409A (en) *	1989-09-28	1992-02-18	Monsanto Company	Method of increasing specific activity of t-pa
US5326700A (en) *	1990-11-06	1994-07-05	Eli Lilly And Company	DNA sequences encoding t-PA derivatives with cleavable sites
US5661001A (en) *	1993-08-04	1997-08-26	Ciba-Geigy Corporation	High molecular weight desulphatohirudin
US5981227A (en)	1995-02-09	1999-11-09	Movartis Ag	Process for the production of proteins

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4775622A (en) *	1982-03-08	1988-10-04	Genentech, Inc.	Expression, processing and secretion of heterologous protein by yeast
AR241654A1 (es) *	1982-05-05	1992-10-30	Genentech Inc	Procedimiento para producir activador de plasminogeno de tejido humano.
GB2125047B (en) *	1982-08-09	1986-02-19	Ciba Geigy Ag	Yeast hybrid vectors and their use for the production of polypeptides
EP0174835A1 (en) *	1984-09-11	1986-03-19	The Upjohn Company	Human tissue plasminogen activator and recombinant DNA compounds
DK175327B1 (da) *	1984-10-01	2004-08-23	Integrated Genetics Inc	Replicerbar ekspressionsvektor og rekombinant DNA-molekyle, som indkoder aktiv human livmodervævsplasminogen-aktivator, pattedyrscelle transformeret med vektoren og fremgangsmåde til fremstilling af aktiv human vævsplasminogen-aktivator (TPA)

1984
- 1984-11-19 DE DE8484810564T patent/DE3479520D1/de not_active Expired
- 1984-11-19 EP EP84810564A patent/EP0143081B1/en not_active Expired
- 1984-11-19 FI FI844544A patent/FI86746C/fi not_active IP Right Cessation
- 1984-11-19 GR GR80966A patent/GR80966B/el unknown
- 1984-11-19 PH PH31460A patent/PH22337A/en unknown
- 1984-11-19 PT PT79518A patent/PT79518B/pt not_active IP Right Cessation
- 1984-11-19 DD DD84269628A patent/DD229151A5/de not_active IP Right Cessation
- 1984-11-20 NZ NZ210266A patent/NZ210266A/xx unknown
- 1984-11-20 DK DK551084A patent/DK164941C/da not_active IP Right Cessation
- 1984-11-20 AU AU35719/84A patent/AU595478B2/en not_active Ceased
- 1984-11-20 IE IE2965/84A patent/IE57699B1/en not_active IP Right Cessation
- 1984-11-20 HU HU844309A patent/HU201115B/hu not_active IP Right Cessation
- 1984-11-20 NO NO844618A patent/NO844618L/no unknown
- 1984-11-20 IL IL73568A patent/IL73568A/xx unknown
- 1984-11-20 JP JP59243529A patent/JPS6119489A/ja active Pending
- 1984-11-21 ES ES537828A patent/ES8609471A1/es not_active Expired
- 1984-11-21 KR KR1019840007284A patent/KR930002889B1/ko not_active Expired - Lifetime

Also Published As

Publication number	Publication date
KR930002889B1 (ko)	1993-04-12
HU201115B (en)	1990-09-28
FI844544L (fi)	1985-05-22
JPS6119489A (ja)	1986-01-28
IL73568A (en)	1992-07-15
PT79518A (en)	1984-12-01
PT79518B (pt)	1986-12-12
DK551084A (da)	1985-05-22
EP0143081B1 (en)	1989-08-23
EP0143081A3 (en)	1987-01-07
NO844618L (no)	1985-05-22
FI844544A0 (fi)	1984-11-19
KR850003733A (ko)	1985-06-26
DE3479520D1 (en)	1989-09-28
FI86746B (fi)	1992-06-30
ES537828A0 (es)	1986-07-16
DK164941B (da)	1992-09-14
AU3571984A (en)	1986-03-20
GR80966B (en)	1985-03-15
PH22337A (en)	1988-08-12
IE842965L (en)	1985-05-21
FI86746C (fi)	1992-10-12
EP0143081A2 (en)	1985-05-29
DK164941C (da)	1993-02-01
ES8609471A1 (es)	1986-07-16
DK551084D0 (da)	1984-11-20
HUT36185A (en)	1985-08-28
IL73568A0 (en)	1985-02-28
IE57699B1 (en)	1993-03-10
AU595478B2 (en)	1990-04-05
NZ210266A (en)	1988-11-29

Legal Events

Date	Code	Title	Description
1995-09-14	ENJ	Ceased due to non-payment of renewal fee

Publication	Publication Date	Title
DE3885668T2 (de)	1994-05-05	Kluyveromyces als Wirtsstamm.
DE3686136T2 (de)	1992-12-17	Fibrinolytisches agens.
DE3316297C2 (es)	1989-09-21
DE3382760T2 (de)	1995-03-02	Herstellung von funktionellen menschlichen Urokinasepolypeptiden.
DE3751128T2 (de)	1995-07-20	Rekombinante gereinigte Protease, Nexin.
FI86746C (fi)	1992-10-12	Foerfarande foer framstaellning av maensklig vaevnads-plasminogenaktivator (tpa) med hjaelp av saccharomyces cerevisiae -jaest och i foerfarandet anvaenda hybridvektorer
DE69428719T2 (de)	2002-08-08	Für das yap3 signalpeptid kodierendes dna-konstrukt
DE3881776T2 (de)	1993-11-18	DNS-Konstruktionen, enthaltend eine Kluyveromyces-alpha-Factor-Leadersequenz zur Leitung der Sekretion von heterologen Polypeptiden.
DE69011853T2 (de)	1994-12-15	System zur bearbeitung von hefe, welches eine zur bearbeitungsstelle benachbarte negativ geladene aminosäure beeinhaltet.
DE68923298T2 (de)	1996-01-11	Gewebe-plasminogenaktivator mit zymogenen oder fibrinspezifischen eigenschaften.
DE68923123T2 (de)	1995-11-30	Herstellung von Proteinen.
DE69229126T2 (de)	1999-12-30	Verfahren zur Herstellung von Thrombin
DD218118A5 (de)	1985-01-30	Verfahren zur herstellung eines hefe- oder nichthefepolypeptids
EP1472346A2 (de)	2004-11-03	Verfahren zur herstellung von rekombinanten proteinen in mikroorganismen
DE3851259T2 (de)	1994-12-15	Mutierter t-PA mit Kringle-Ersatz.
DE3752008T2 (de)	1997-08-14	Hybride Plasminogenaktivatoren
DE3537176A1 (de)	1986-07-10	Expression eines plasminogenaktivators in hefe
DE3853100T2 (de)	1995-08-03	Gewebs-Plasminogen-Aktivator-Analoge mit modifizierten Wachstumsfaktordomänen.
EP0408945B1 (de)	1995-12-13	Plasmide, deren Herstellung und deren Verwendung bei der Gewinnung eines Plasminogenaktivators
DE3888386T2 (de)	1994-07-14	Verfahren zur Herstellung von Proteinen.
EP0496327B1 (de)	2001-08-16	Verfahren zur Herstellung von Polypeptiden mit Prourokinase-Aktivität
WO1996001312A1 (de)	1996-01-18	Nicht-glykosylierte plasminogenaktivator-derivate und ihre verwendung bei erhöhtem blutungsrisiko
DE3887425T2 (de)	1994-06-23	BAR1-Sekretions-Signal-Sequenz.
WO1992004444A1 (en)	1992-03-19	Methods for producing acyloxyacyl hydrolase
EP0917567A1 (de)	1999-05-26	Thrombinaktivierbarer plasminogenaktivator